Use of a Thrombin Fibrin Sealant in Reducing Blood Loss in Revision Hip Arthroplasty.

We present a retrospective evaluation assessing the use of a novel fibrin sealant, Quixil(®) (OMRIX Biopharmaceuticals S.A.) in reducing blood transfusions following revision total hip replacement surgery.

Outcomes of dual modular cementless femoral stems in revision hip arthroplasty.

With an increasing number of primary hip replacements being performed every year, the burden of revision hip arthroplasty, for septic and aseptic loosening, recurrent dislocation or periprosthetic fracture, is also increasing. In recent years, different approaches to revising the femoral prosthesis have emerged; including both cemented and cementless techniques. With a stable cement mantle and good bone quality, or through the use of impaction bone grafting when bone stock is lacking, it is possible to re-cement a femoral prosthesis.